US equities |
MU $1,097.39 ▲+0.00% NVDA $230.86 ▲+0.00% SNDK $1,787.69 ▲+0.00% STX $945.57 ▲+0.00% WDC $462.56 ▲+0.00% NKE $35.15 ▲+0.00% MSTR $160.50 ▲+0.00% INTC $120.00 ▲+0.00%
FinancialContent

Kairos Pharma, Ltd. Common Stock (NY:KAPA)

1.560 UNCHANGED
Delayed Quote Updated: 8:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kairos Pharma, Ltd. Common Stock

< Previous 1 2 3 Next >
NetworkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present KROS-101 Research at Discovery on Target Conference
Via Investor Brand Network
News headline image
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) CEO to Present at H.C. Wainwright 28th Annual Global Investment Conference
Via Investor Brand Network
News headline image
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
From Kairos Pharma, Ltd
Via Business Wire
News headline image
Kairos Pharma Announces 1-for-7 Reverse Stock Split
From Kairos Pharma, Ltd
Via Business Wire
TinyGemsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Collaborates With Bayer to Evaluate Combination Therapy for Advanced Prostate Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Favorable Interim Phase 1 Safety Data for ENV-105 in EGFR-Mutated Lung Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
From Kairos Pharma, Ltd
Via Business Wire
TinyGemsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Pipeline Expansion and Clinical Milestones in Mid-Year Shareholder Update
Via Investor Brand Network
News headline image
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives 2026 Healthcare Innovation Award for Drug Resistance Research
Via Investor Brand Network
News headline image
Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at LD Micro Invitational XVI
Via Investor Brand Network
TinyGemsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Sets Virtual Annual Meeting, Discloses Going Concern Notice
Via Investor Brand Network
Topics Regulatory Compliance
News headline image
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Earns 2026 Pinnacle Award for Biotech Innovation in Cancer Drug Resistance
Via Investor Brand Network
News headline image
Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
From Kairos Pharma, Ltd
Via Business Wire
News headline image
Kairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA
From Rosen Law Firm, P.A.
Via Business Wire
News headline image
Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA
From The Rosen Law Firm, P.A.
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Enters Binding Terms To Acquire CL-273 For EGFR-Mutant Lung Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Signs Term Sheet to Acquire Two Clinical-Stage NSCLC Assets
Via Investor Brand Network
News headline image
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
From Kairos Pharma, Ltd
Via Business Wire
TinyGemsBreaks – To Participate In DealFlow Discovery Conference
Via Investor Brand Network
News headline image
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives Clinical Trials Arena Research and Development Award for Advanced Prostate Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2025 Milestones and Clinical Progress in CEO Letter to Shareholders
Via Investor Brand Network
News headline image
Kairos Pharma Provides Shareholder Update
From Kairos Pharma Ltd
Via Business Wire
< Previous 1 2 3 Next >